· Executive summary………..………………………………………..3 · Introduction…………………………………………….…………...5
· Section 1- Environment/ Industry analysis….................…………....5
· Section 2- Company Description………….....……………………..7
· Section 3- Financial analysis………………...………………….…..8
· Section 4- Marketing Strategy………………………...……...…...10
· Section 5- Use of Information Technology………..………...…….11
· Section 6- Ethical/ Environmental Issues….....………….………..12

· Conclusion…………………………................................................13

Executive Summary In 2001 Abbott was assessed by Jim Collins in his book “Good to Great” and deemed a worthy investment. Eleven years later Abbott has sustained that high level of performance as a producer in the healthcare and pharmaceutical industry. This performance can be attributed to their consistent financial growth over its competitors.
The company competes among the healthcare industry producing pharmaceuticals, medical devices and nutritional products. Abbott is among several large companies that have dominated the industry for about half a century.
Abbott has experienced a consistent increase in revenue over the past five years. Due to recent acquisitions, the company has had increasing operating costs, but stable profits. Notable financial risks of the company are their smaller product pipeline and smaller cash cushion compared to competitors. Abbott Labs marketing branch is what brings the company together through new emerging markets and ideas to reach out to their patients. As the company is splitting and branching off, this will give the company time and money to focus on each department individually. A big part of Abbott’s Strategy is to learn and further develop their company to generate sales and opportunities while following a set code of guidelines to ensure